Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bausch + Lomb Corporation BLCO on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...

Bausch + Lomb Corporation , a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in ...

Ollama Inc., the largest artificial intelligence platform connecting developers to open models, today announced it has raised ...

Halos Around Lights at Night You notice a coloured ring around a streetlight or an oncoming headlight and assume your eyes ...

Optometrists Anastasia Logotheti, OD, and Andrew Pucker, OD, discuss strategies for mitigating the impact of topical glaucoma ...

Does the type of primary angle-closure glaucoma (PACG) a patient has influence how well they respond to combined cataract and ...

It plays a significant role in the development of conditions that can lead to blindness. But most of these can be prevented ...

I heard Wayne had to give up driving because he is blind from glaucoma, but I saw him at the cafe reading a newspaper. I’m struggling to make sense of that: what is glaucoma?” ...

Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million ...

In a large-scale study, Chinese scientists have found that intense artificial lighting in the evening significantly increases ...